EAACI Congress 2025

Back
13 - 16 June 2025 Glasgow, United Kingdom

The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Sunday 15 Jun, 12:45 PM - 12:45 PM Glasgow, United Kingdom